Skip to main content
padlock icon - secure page this page is secure

Pilot study of nebulized surfactant therapy for neonatal respiratory distress syndrome

Buy Article:

$52.00 + tax (Refund Policy)

Thirty‐four spontaneously breathing newborns with respiratory distress syndrome (RDS) requiring nasal continuous positive airway pressure (CPAP) and an arterial‐to‐alveolar oxygen tension ratio (a/A PO2) of 0.15‐0.22 were randomized to treatment with nebulized surfactant (Curosurf®) or to serve as controls. All children were first supported by nasal CPAP according to normal clinical routines. Surfactant was administered using a modified Aiolos® nebulizer, and a total of 480 mg was aerosolized in each case. The control group received no nebulized material, but had the same CPAP support. Acid‐base status and a/A PO2 were determined at regular intervals before, during and after surfactant administration. Both groups included in the study were similar with regard to gestational age, birthweight, steroids given before birth, sex and Apgar scores as well as a/A PO2 when entering the study. There were no significant differences between the groups in a/A PO2 1‐12 h after randomization, number of infants needing mechanical ventilation, time on ventilator or CPAP. Two children in the treated group developed bronchopulmonary dysplasia. No side effects of the surfactant therapy were noted.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Continuous positive airway pressure; nebulization; neonatal; respiratory distress syndrome; surfactant

Document Type: Research Article

Affiliations: 1: Sachsska Hospital Stockholm, Sweden 2: Stockholm; Örebro Medical Centre Hospital Stockholm, Sweden 3: Örebro; Malmö University Hospital Stockholm, Sweden

Publication date: April 1, 2000

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more